It has been reported that the local injection with 5 fluorouracil (5-FU) endoscopically (EC), could have a favorable result in patients with early gastric cancer. Our objective was to evaluate the result of the EC with 5-FU, in patients with AGC who had contraindications for surgery or rejected it. Methods. Three patients with AGC were selected and evaluated for EC; The diagnosis was made through endoscopies and gastric biopsies. Macroscopically, one patient had Bormann HI, another a synchronic lesion type He. Histologically there were intestinal adenocarcimas. Patients (PI, P2, P3) were respectively 74, 83 and 81 years old. All of them were men. PI and P3 had rejected surgery, P2 presented contraindications to surgery due to chronic renal failure and elevated surgical risk. The absence of peroneal and hepatic invasion was made by ultrasound CT and abdominal laparoscopy. The EC was performed with 5-FU, giving it with a sclerotherapy injector, over the submucosa on the lesion external border and in the surrounding tissue macroscopically normal. 250 mg of 5 FU were injected per session every 7 days for 4 weeks. A second session took place after nine months for two of the patients (P2 and P3), PI rejected this last session. Results. Good tolerance was observed without adverse reactions. A reduction on the size of the lesions was achieved in the first nine months, 40% for PI, 50% for P2 and 60% for P3. A progress on PI and P2 was observed between the 12th and the 15th months. The overall survival was 22 months for PI, 40 for P2 and 21 for P3. Conclusion. The EC with 5-FU constitutes a valid palliative therapeutical option in a certain group of patients with advanced gastric cancer, without adverse reactions, conservation of their lifestyle and overall survival.
展开▼
